This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By re-engineering existing approaches that have already shown clinical promise, there is potential to bring further benefit to the patient community in its fight against cancer. Since then, several next-generation antibodies have been engineered with modifications that enable them to better engage with immune cells.
In this episode, Blake Williams takes us on a wild journey through his career as a Field Clinical Engineer (FCE), shedding light on the incredible impact of neuromodulation on the lives of patients. I am a field clinical engineer. People come from sales, clinical, and engineers. Nursing to engineering.
The US Food and Drug Administration (FDA) has approved commercial production at Bristol Myers Squibb’s newest cell therapy manufacturing facility in Devens, Massachusetts. Each batch of engineered T cells is manufactured individually and infused back to the original cancer patient.
Tyber Medical LLC, the global, leading private-label medical device provider for major orthopedic trauma, extremity, and spine companies, has been awarded a U.S. Food and Drug Administration (FDA) 510(k) clearance for its new NiTy+ One-Shot Staple Fixation System. Are you hiring?
Misinformation and Hallucinations : Generative AI platforms may create content that is inaccurate, outdated, or off-labelviolating FDA regulations. One misstep can lead to warning letters, product recalls, or reputational damageespecially when AI is used to engage vulnerable populations.
Using FDA-approved messaging and ensuring transparent disclaimers are critical in avoiding regulatory issues. Brands must adhere to HIPAA, FDA, and GDPR guidelines when collecting and using patient data. The future of pharma marketing is digitalare you ready to lead the way? However, compliance is key.
Multi-Channel Retargeting : Using platforms like search engines, social media, and programmatic ad networks expands reach and improves conversion rates. Frequency Capping : Overexposing users to ads can lead to fatigue. Marketers must ensure that their campaigns adhere to FDA, HIPAA, and GDPR guidelines to avoid legal complications.
This is a crucial first step in our path to make the Maestro Brain Model the ‘engine’ in our navigation system supporting multiple new applications in the future. The unique shape representation in Maestro will provide reproducible lead placement for deep brain stimulation and micro electrode recording. Are you hiring?
So how can pharma brands maximize their return on investment (ROI) while ensuring compliance with FDA and HIPAA regulations ? The answer is simple search engines and social platforms are where patients and HCPs find information. Lead Generation: Drive patient education sign-ups, HCP event registrations, and drug sample requests.
the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance imaging (MRI) device for imaging of the brain, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the company’s upgraded AI-powered software. Hyperfine, Inc.,
Face-to-face HCP visits dwindled, patients turned to search engines for symptom answers, and telehealth became the norm. SEO and Content Strategy Search engines remain a key source of medical information. Teams that prioritize innovation, compliance, and data will not just survivethey will lead. Frequently Asked Questions 1.
But how can pharma marketing teams maximize the impact of PPC campaigns while ensuring compliance and generating high-value leads? Brand Authority: By appearing at the top of search engine results, pharmaceutical companies increase brand credibility among HCPs. Feature clear, regulatory-compliant content.
By creating lifelike, three-dimensional models, 3D visualization enables developers, engineers, and stakeholders to see and interact with a device before it ever reaches the production line. This approach allowed them to perfect the design in just 7-10 iterations, ultimately speeding up the process of gaining FDA approval.
Staying informed on pharma marketing news ensures you’re not caught off guard when a new FDA guidance is issued or when a competitor launches a disruptive campaign. Its not just a news sourceits a knowledge engine. And lets not forget the tightening regulatory environment around digital promotion and data privacy.
The most prominent among them include: AI misinterpretation of critical information: As an example, a team might ask ChatGPT to answer a question, and the AI engine may deliver an impressive volume of information, while misaligning with the core business, leading to conclusions that are either overvalued or flat-out wrong.
The PureTech group company – which scored the first FDA and EMA approvals for a DTx for attention-deficit hyperactivity disorder (ADHD) – is developing AKL-T01 to tackle cognitive impairments that can affect people with SLE.
For example, a query for “rare disease drug approval” would include results for the Orphan Drug Act from the FDA. The email’s text-based search function is unlikely to return the correct result unless you use the precise word, which inevitably leads to multiple search attempts and time lost hunting through emails.
Therefore, it is essential that we broaden the scope of medical trials and research,” commented Tinamarie Duff, DAWN Global People & Business Resource Group Lead. The US Food and Drug Administration (FDA) recently published a new draft guidance to support companies in enrolling more ethnically diverse trial populations. .
With platforms like Bing, LinkedIn, and programmatic networks, pharma marketers can scale efforts across search engines and display placements. Landing pages should also adhere to FDA requirements, clearly displaying ISI (Important Safety Information) and PI (Prescribing Information) where applicable. Clear calls to action (e.g.,
They must be highly targeted, compliant with FDA and HIPAA guidelines, and designed to generate meaningful interactions rather than just impressions. If a campaign is underperforming, adjusting copy, visuals, or targeting parameters can lead to improved results. Lead generation (measured by webinar sign-ups or whitepaper downloads).
The US Food and Drug Administration (FDA) has granted approval to commence commercial production at Bristol Myers Squibb’s new advanced cell therapy manufacturing facility in Devens, Massachusetts. Each engineered T cell batch is manufactured separately and infused back into the cancer patient.
Zeta’s computer vision engine ensures maintained accuracy by automatically registering multiple times a second, accounting for patient movement. Zeta Surgical was founded by Harvard graduates and faculty and is backed by leading investors. To learn more, visit: www.zetasurgical.com. Are you hiring?
The US Food and Drug Administration (FDA) has granted an Orphan Drug Designation to Editas Medicine’s gene therapy EDIT-301 in sickle cell disease, based on an April 27 announcement. The US agency previously granted the Orphan Drug Designation to EDIT-301 for its study in beta thalassemia, in May 2022.
Rapid Medical , a leading developer of advanced neurovascular devices, announces FDA 510(k) clearance for TIGERTRIEVER 13 for large vessel occlusions at the 2022 Society of NeuroInterventional Surgery’s (SNIS) 19th Annual Meeting in Toronto. TIGERTRIEVER 17 and 21, COMANECI , and COLUMBUS /DRIVEWIRE are CE marked and FDA cleared.
This partnership will hopefully lead to patients being able to use BCI devices in the comfort of their own home. . Co-Founder & Chairman of Blackrock Neurotech and Professor and Chair at the Department of Electrical and Computer Engineering at University of Utah, about the company’s latest technology.
Axial3D, a leader in medical segmentation and 3D solutions, today announced that it is the first to receive FDA clearance for an automated, AI-driven, cloud-based segmentation platform for orthopedic trauma, orthopedic, maxillofacial, and cardiovascular applications. Are you hiring?
Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Pounce LP (Low Profile) Thrombectomy System. Surmodics, Inc. mm to 6 mm in diameter. About Surmodics, Inc.
The new technologies will also overcome the manufacturing bottlenecks in delivering advanced engineered cell products. Currently, there are six CAR T cell therapies that received approval from the US Food and Drug Administration (FDA) and approximately 560 programmes in ongoing studies.
If a misinterpretation exists between engineers and testers on the solution developed, then such requirements will have higher risks on the entire lifecycle. For example, insights from healthcare providers (HCPs) might be filtered through a medical science liaison’s interpretations, leading to gaps in the captured requirements.
In the past year, Hemgenix has been granted approval by the US Food and Drug Administration (FDA) and has received conditional marketing authorisation from the European Commission (EC) and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This followed positive results from CSL’s Phase III HOPE-B trial (NCT03569891).
SPK-9001 is a novel, investigation vector containing a bio-engineered adeno-associated virus (AAV) capsid (protein shell) and a high-activity human coagulation FIX gene. during the lead-in pre-treatment period of at least six months. for the 12 months from week 12 to month 15 compared to an ABR of 4.43
Martin Vogel, Janssen’s Therapeutic Area Lead Oncology for the Europe, Middle-East and Africa (EMEA) region shared with EPR what makes the BsMAb promising for treating this indication. They are not US Food and Drug Administration (FDA)-approved for these patients due to the lack of benefit. Personalized medicine at FDA.
Food and Drug Administration (FDA) has granted 510(k) clearance to the Axiom PSR System for use with the company’s Kinos Axiom Total Ankle System. The convergence of our inhouse 3d printing capabilities, advanced engineering, and clinically focused research teams allows us to provide the next generation patient-specific devices.
As ISPE GAMP 5 Second Edition notes in the preface “Operating in a highly regulated industry may lead practitioners to apply prescriptive and rigid compliance-based approaches that are not commensurate with and not effective in managing any actual risk to the product and the patient.” FDA, 2022. . About the authors.
Thanks to kind support from Biomed Israel , the leading international Life Science and HealthTech conference in Israel (see more below), we met with Ronan Castro, the CEO of Human Xtensions at the company’s offices in Netanya, Israel.
Not only can impurities lead to adverse effects in patients, but they can also introduce product variability. The risks linked to contamination have led regulatory bodies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to implement strict requirements on process characterisation and validation.
This leads to substantial damage to healthy tissues and too often results in poor outcomes. The FDA looked at the data, saw it promising, and asked for a small feasibility study in the U.S. We hope to see Alpha TAU presenting its technology at Biomed Israel , the leading international Life Science and HealthTech conference in Israel.
More about the gene therapy The one-time gene therapy contains a “bio-engineered adeno-associated virus (AAV) capsid and a high-activity variant of human coagulation FIX gene”, Pfizer shared. DURVEQTIX was approved by the US Food and Drug Administration (FDA) for haemophilia B as BEQVEZ TM in April this year.
2 Driven by the success of FMTs with clinical efficacy in several indications 3-6 and the first two FDA-approved donor-derived products on the market for recurrent Clostridioides difficile infections, 7,8 a new and promising trend is emerging that combines the ‘whole ecosystem’ of FMTs with rational consortia design. Microbiome.
1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. If you apply the right AI engines, you will get increasingly better insights. At the same time, MSLs are being asked to help inform brand strategy with their learnings from talking to leading healthcare professionals.
Regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) place great importance on data integrity in the pharmaceutical/life science industry. Lack of proper training can lead to errors, omissions, or intentional data manipulation, which can compromise data.
Introduction Pharma marketing is changing, and pay-per-click advertising (PPC) is leading the charge. Lets explore the best PPC strategies for pharma brands and how they can improve brand awareness, lead generation, and return on investment (ROI). This level of targeting helps drive qualified leads and higher engagement rates.
The first FDA-approved gene therapies (Luxturna and Kymriah) entered the market in 2017. Today, the number of FDA and EMA-approved gene therapies is on the rise, with many more currently under development. The future of cell and gene therapies.
For instance, Google Cloud released Real-World Insights a real-world data management platform which it co-developed with the FDA in 2019. It needs to be performed with a benchmark, an FDA-approved device.”. Meanwhile, DCT start-ups are pairing up with healthcare and service providers to expand their clinical offerings.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content